Quantcast

Latest Doxorubicin Stories

2014-07-17 04:20:54

Encapsula NanoSciences, a company specializing in liposome research and development, announces the release of two new liposome-­based products for consumer use NASHVILLE, Tenn., July 17, 2014 /PRNewswire/ -- Encapsula NanoSciences announces the release of two new liposome ­based products? Curcusome® and Taurosome(TM). Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder ­release cap for consumer ease. Taurosome(TM) or...

2014-06-20 08:24:10

-- Transaction Forms Fully-Integrated Oncology Discovery and Development Company LAWRENCEVILLE, N.J., June 20, 2014 /PRNewswire/ -- Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other...

2014-06-02 08:29:28

QUEBEC CITY, June 2, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster was presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster #TPS5630 titled, "ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108)in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", D. S. Miller,...

2014-05-22 08:29:15

QUÉBEC CITY, May 22, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50(th) Annual Meeting...

2014-05-16 08:26:24

Abstract Presents a Retrospective Analysis of the Company's 701 Patient HEAT Study and Compelling Data Showing Enhanced Efficacy When Radiofrequency Ablation is Combined with ThermoDox and When Heating Time of the RFA Procedure is Greater Than 45 Minutes LAWRENCEVILLE, N.J., May 16, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that an abstract on its Phase III HEAT Study of ThermoDox, the Company's proprietary...

2014-05-09 20:11:01

NCSU Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell. “This is an efficient, fast-acting way of delivering drugs to cancer cells and triggering cell death,” says Dr. Ran Mo, lead author of a paper...

2014-04-17 16:26:55

LAGUNA HILLS, Calif., April 17, 2014 /PRNewswire/ -- NanoSmart(®) and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration agreement to explore the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors. The joint project combines NanoValent's hybrid polymerized liposomal nanoparticle (HPLN), which can be loaded with...

2014-03-19 23:26:27

A new study indicates that an investigational drug for relapsed Non-Hodgkin’s Lymphoma called pixantrone (Pixuvri) is safer for the heart than the current front-line treatment. Raleigh, NC (PRWEB) March 19, 2014 Research published in Reproductive Toxicology and reported by the Non-Hodgkin’s Lymphoma Center suggests that there may be a better treatment option for people with relapsed or refractory (recurrent) aggressive Non-Hodgkin’s Lymphoma. Non-Hodgkin’s Lymphoma patients who...

2014-03-19 08:29:44

New Investment Will Fund the Company's Upcoming Phase 2 Clinical Trial in Sarcoma Patients BIRMINGHAM, Ala., March 19, 2014 /PRNewswire/ -- Gem Pharmaceuticals announced today that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to fund the Company's upcoming Phase 2 clinical trial of GPX-150 in sarcoma patients. These funds will be invested over the course of the trial. Photo -...

2014-03-07 23:21:39

A new article in a top medical journal says appropriate use of a safer chemotherapy drug could open up more treatment options for Non-Hodgkin’s Lymphoma patients. Raleigh, NC (PRWEB) March 07, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article published in Leukemia & Lymphoma journal suggesting that an alternative to a popular Non-Hodgkin’s Lymphoma drug can reduce the risk of heart problems and help more patients. This is especially good news for elderly...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.